Cancer Immunology Immunotherapy

Article	Citations
Pembrolizumab and atezolizumab in triple-negative breast cancer	141
Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors	129
An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma	99
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis	94
Chemotherapy: a double-edged sword in cancer treatment	91
Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma	88
Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC	83
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives	75
Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer	74
Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients	71
Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma	70
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity	68
OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway	65
Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC)	63
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells	61
The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer	60
ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer	60
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy	57
PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade	56
Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models	56
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%	54
A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment	53
Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer	51
Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma	47
Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab	45

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disea	45
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial	43
Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma	43
Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma	43
Expression of the immune checkpoint VISTA in breast cancer	42
Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer	42
Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer	42
Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase	42
Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis	41
Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors	39
Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors	39
Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers	39
Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study	39
Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome	37
IL-12 regulates the expansion, phenotype, and function of murine NK cells activated by IL-15 and IL-18	37
In vitro and in vivo evaluation of anti-tumoral effect of M1 phenotype induction in macrophages by miR-130 and miR-33 containing exosomes	36
Characterization of CD103+ CD8+ tissue-resident T cells in esophageal squamous cell carcinoma: may be tumor reactive and resurrected by anti-PD-1 blockade	36
Regulatory T cells promote glioma cell stemness through TGF-β–NF-κB–IL6–STAT3 signaling	36
Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment	36
In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy	35
TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer	35
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer	35
PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas	35
Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site	35
Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma	34
CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer	34
ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas	33
The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade	33
Blockade of CD73 delays glioblastoma growth by modulating the immune environment	33
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China	32
Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncol	32
Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis	32
Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab	32
CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration	31
Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors	31
Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis	31
Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients	31
Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis	31
The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte	30
Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer	29
Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials	29
Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment	29
CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors	29
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors	29
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma	29
Curdlan, zymosan and a yeast-derived β-glucan reshape tumor-associated macrophages into producers of inflammatory chemo-attractants	29
Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab	29
Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer	28
Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer	28
Differential immune microenvironmental features of microsatellite-unstable colorectal cancers according to Fusobacterium nucleatum status	28

IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma	27
Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape	27
Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models	27
The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer	27
LncRNA MIR155HG induces M2 macrophage polarization and drug resistance of colorectal cancer cells by regulating ANXA2	27
Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors	27
Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers	27
Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC)	27
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy	26
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression	26
Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis	26
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL	26
The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer	26
Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodi	26
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells	26
Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1	26
Absolute quantification of tumor-infiltrating immune cells in high-grade glioma identifies prognostic and radiomics values	25
Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma	25
Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients	25
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC	25
Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions	25
Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma	25
Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors	24
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study o	24
Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors	24
Activated HIF1α of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer	24
T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer	24
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer	24
Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18	23
CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer	23
Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TA	23
Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies	23
Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice	23
Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment	23
Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study	23
Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy	23
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study	23
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas	23
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR	22
Interleukin-38 promotes tumor growth through regulation of CD8+ tumor-infiltrating lymphocytes in lung cancer tumor microenvironment	22
Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy	22
Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience	22
LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway	22
Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC	22
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma	22
Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies	22
Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer	22
Prognostic role of the systemic immune–inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration	22
Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study	21
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia	21
Let-7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL-13 and IL-10	21
Metformin inhibits human non-small cell lung cancer by regulating AMPK–CEBPB–PDL1 signaling pathway	21
Interleukin-12 as an in situ cancer vaccine component: a review	21
Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells	21
Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC)	21
Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis	21
miR-34a induces immunosuppression in colorectal carcinoma through modulating a SIRT1/NF-κB/B7-H3/TNF-α axis	21
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)	21
Characterising the prognostic potential of HLA-DR during colorectal cancer development	21
Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer	20
Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy	20
Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis	20
Micro-environmental cross-talk in an organotypic human melanoma-in-skin model directs M2-like monocyte differentiation via IL-10	20
Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations	20
High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient	20
Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review	20
Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer	20
Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer	20
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients	20
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors	20
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma	19
Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy	19
Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial	19
Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide	19
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review	19
Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports	19
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors	19
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma	19
Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy	18
Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors	18

Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study	18
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature	18
Exhaustion in tumor-infiltrating Mucosal-Associated Invariant T (MAIT) cells from colon cancer patients	18
Epstein–Barr virus (EBV) and polyomaviruses are detectable in oropharyngeal cancer and EBV may have prognostic impact	18
Rapid noninvasive detection of bladder cancer using survivin antibody-conjugated gold nanoparticles (GNPs) based on localized surface plasmon resonance (LSPR)	18
A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated he	18
Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient	18
Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature	18
Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8+ T cells	18
APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application	18
Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment	18
18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer	18
Immune cell profiles in the tumor microenvironment of early-onset, intermediate-onset, and later-onset colorectal cancer	18
Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?	18
The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma	18
Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody	18
A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors	17
Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma	17
NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences	17
PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients	17
Comparative immunomodulatory properties of mesenchymal stem cells derived from human breast tumor and normal breast adipose tissue	17
Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy	17
Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab	17
Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors	17
Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma	17
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study	17
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study	17
Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma	17
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis	17
PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures	17
Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity	17
Lactate modulates microglia polarization via IGFBP6 expression and remodels tumor microenvironment in glioblastoma	17
The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations	17
Next-generation humanized patient-derived xenograft mouse model for pre-clinical antibody studies in neuroblastoma	17
Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature	16
Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors	16
Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer	16
Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters	16
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade	16
Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis	16
Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab	16
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186	16
In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes	16
Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma	16
CAR19/22 T cell therapy in adult refractory Burkitt’s lymphoma	16
Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy	16
The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study	16
Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment	16
Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma	16
T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model	16
PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model	16
Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma	15
Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer	15
Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer	15
Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21	15
Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer	15
TGF-βR inhibitor SB431542 restores immune suppression induced by regulatory B–T cell axis and decreases tumour burden in murine fibrosarcoma	15
Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer	15
Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients	15
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIM	15
Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL	15
A novel immune-related gene-based prognostic signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy	15
Evaluation of cytokines in the tumor microenvironment of lung cancer using bronchoalveolar lavage fluid analysis	15
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma	15
Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody	15
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial	15
B7-H3 is spliced by SRSF3 in colorectal cancer	15
TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of γδ T cells	15
The liposome of trehalose dimycolate extracted from M. bovis BCG induces antitumor immunity via the activation of dendritic cells and CD8+ T cells	15
Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program	14
Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance	14
Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma	14
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy	14
Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients	14
Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions	14
Platelet-expressed immune checkpoint regulator GITRL in breast cancer	14
Metabolomic profiling of tumor-infiltrating macrophages during tumor growth	14
Functional virus-specific memory T cells survey glioblastoma	14
CD74+ macrophages are associated with favorable prognosis and immune contexture in hepatocellular carcinoma	14
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2	14
IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity	14
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer	14
PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung	14
Are we ready to use TMB in breast cancer clinical practice?	14
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors	14
Multi-antigen DNA vaccine delivered by polyethylenimine and Salmonella enterica in neuroblastoma mouse model	14
Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma	14
Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody	14
Circ-HSP90A expedites cell growth, stemness, and immune evasion in non-small cell lung cancer by regulating STAT3 signaling and PD-1/PD-L1 checkpoint	13
Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses	13
A TLR4–TRIF-dependent signaling pathway is required for protective natural tumor-reactive IgM production by B1 cells	13
Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes	13
Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies	13
Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas	13
Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cells	13